Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
clinical trial
Advertisement
BrainBox TBI Study Reveals Breakthrough in Concussion Diagnosis
RICHMOND, VA – October 17, 2025: BrainBox Solutions has published a major analysis in JAMA Network OPEN from its...
NEXTBIOMEDICAL Launches U.S. Pivotal Trial for Nexsphere-F™ in Knee OA
SEOUL, South Korea, Oct. 13, 2025 — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), a South Korea-based innovative medical device company,...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Adcendo Secures FDA Fast Track for ADCE-D01 Targeting Soft Tissue Sarcoma
COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates...
Advertisements
Envoy Medical Moves Closer to Market with FDA Trial Approval
ST. PAUL, Minn., Oct. 8, 2025 — Envoy Medical, a pioneer in fully implanted hearing device technology, has received...
Kura and Kyowa Kirin Launch Trial Targeting FLT3/NPM1 AML
SAN DIEGO and TOKYO, Oct. 1, 2025 — Kura Oncology and Kyowa Kirin have announced the first patient dosing...
Glenmark Launches Phase 3 Global Study of Envafolimab for Lung Cancer
MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...
Tagworks Advances TGW101 in Phase 1 Trial for Solid Tumors
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
REGENXBIO Reports Positive 12-Month Data from RGX-121 CAMPSIITE® Trial in MPS II
EGENXBIO Inc. (Nasdaq: RGNX) announced positive 12-month pivotal data from its Phase I/II/III CAMPSIITE® trial of RGX-121 (clemidsogene lanparvovec),...
Advertisement
